Phase 3 LANTERN study reduces 30-day SSI risk by 40.5% for OBI
The LANTERN Phase 3 study met its primary endpoint, showing a 40.5% reduction in 30-day surgical site infection risk with nasal photodisinfection plus standard care. Safety was favorable, with only mild, transient adverse events, supported by both Bayesian and frequentist analyses.
5% reduction in 30-day surgical site infection risk when nasal photodisinfection was added to standard care, with the result supported by both Bayesian and frequentist analyses. Safety findings were favorable, with adverse events described as mild and transient.